Download PDF
Thromb Haemost 1959; 03(02): 279-285
DOI: 10.1055/s-0038-1654388
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Influence of Dicoumarol Derivatives on Plasma Fibrinolytic System

Marta Niewiarowska
1   Department of Physiopathology, Institute of Haematology, Warsaw, Poland
,
Zenon Wegrzynowicz
1   Department of Physiopathology, Institute of Haematology, Warsaw, Poland
› Author Affiliations
Further Information

Publication History

Publication Date:
08 June 2018 (online)

Also available at
   Permissions and Reprints

Summary

The influence of some coumarine derivatives (anticoagulant drugs: pelentan [tromexan], sintrom, marcoumar) on plasma fibrinolytic activity has been investigated. The cases studied included a number of patients with coronary thrombosis treated in long-term anticoagulant therapy and rabbits treated with a single dose of the drug.

The anticoagulants have no significant effect either on fibrinogen or plasminogen level. All of the above mentioned drugs cause a prolongation of the euglobulin fibrinolysis time and an increase of the antiplasmin level. These two changes may be correlated to the prolongation of the prothrombin time.

The authors suggest that the described phenomena may be useful for biological and clinical evaluation of anticoagulant drugs.

 

  • References

  • 1 Alexander B, Landwehr G. Evolution of prothrombin conversion accelerator in stored human plasma and prothrombin fractions. Amer. J. Physiol 1949; 159: 332
    PubMedGoogle Scholar
  • 2 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. Biophys 1952; 40: 346
    CrossrefPubMedGoogle Scholar
  • 3 Bachmann F, Duckert F, Geiger H, Baer P, Koller F. Differentiation of factor VII complex. Studies on the Stuart-Prower factor. Thromb. Diath. haem 1957; 1: 169
    PubMedGoogle Scholar
  • 4 Buluk K, Januszko T. Heparyna a fibrynoliza. Patol. pol 1957; 8: 107
    PubMedGoogle Scholar
  • 5 Douglas A. S. A mode of action of coumarin drugs. Brit. med. Bull 1955; 11: 39
    CrossrefPubMedGoogle Scholar
  • 6 Elsner P. Fibrinolyse in Schwangerschaft und Geburt. Fortschritte der Geburtshilfe und Gynäkologie, Nr. S. Karger, Basel; New York: 1957: 6
    Google Scholar
  • 7 Halse T. Fibrinolyse. Freiburg (1948), Cantor ed
    PubMed
  • 8 Irish V. V, Jaques L. B. The effect of dicoumarol upon plasma fibrinogen. Amer. J. Physiol 1945; 143: 101
    PubMedGoogle Scholar
  • 9 Koller F, Loeliger A, Duckert F. Experiments on a new clotting Factor (Factor VII). Acta haemat. (Basel) 1951; 6: 1
    CrossrefPubMedGoogle Scholar
  • 10 Koller F. Le Facteur X. Rev. Hémat 1952; 10: 362
    PubMedGoogle Scholar
  • 11 Kopec M, Niewiarowski S. Czynnosc fibrynolityczna osocza osob zdrowych. Pol. Arch. Med. wewnet 1956; 26: 1322
    PubMedGoogle Scholar
  • 12 Kowalski E, Latallo Z, Niewiarowski S. Untersuchungen über die Aktivierung von Plasminogen und Inaktivierung von Plasmin. Folia haemat. (Lpz.) 1957; 75: 225
    PubMedGoogle Scholar
  • 13 Kowarzyk H, Buluk K. Postepy badan nad krzepnieciem krwi. Postepy Medy-cyny Doswiadczalnej i Higieny 1950; 2: 1
    PubMedGoogle Scholar
  • 14 McElfresh A. E, Özge A. The effect of coumarin drugs upon Plasma Thromboplastin Component. J. Lab. clin. Med 1957; 49: 753
    PubMedGoogle Scholar
  • 14a Niewiarowska M. L’influence de l’hypothermie par refroidissement sur la coagulation du sang et sur la fibrinolyse chez le chat. Rev. Hémat 1957; 12: 650
    PubMedGoogle Scholar
  • 15 Niewiarowski S, Latallo Z. unpublished
    PubMed
  • 16 Quick A. J. Hemorrhagic Diseases. Lea and Febiger; Philadelphia: 1957
    Google Scholar
  • 17 Rechnic M, Siwinska M, Czerwinska B. Antyfibrynolizyna krwi a thrombinogeneza. Arch. Immunol. Ter. Dosw 1957; 5: 347
    PubMedGoogle Scholar
  • 18 Sise H. S, Kumball D. M, Adams D. Plasma Thromboplastin Component Deficiency produced by prolonged administration of prothrombopenic anticoagulants. Proc. Soc. exp. Biol. (N. Y.) 1955; 89: 91
    PubMedGoogle Scholar
  • 19 Smith W. B, Rosenfeld R, Shinovara G. Y. Human plasma fibrinogen levels in various pathological states. Fed. Proc 1951; 10: 371
    PubMedGoogle Scholar
  • 20 Wessler S. Studies on intravascular coagulation, II. A comparison of the effect of dicoumarol and heparin on clot formation in isolated venous segments. J. clin. Invest 1953; 32: 652
    PubMedGoogle Scholar
  • 21 Witte S. Profibrinolysin, Thrombin-Inhibitor und Antithrombin bei Thrombose und während einer antikoagulierender Therapie. Intern. Tagung über Thrombose und Embolie; Basel: 1954
    Google Scholar